Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Exp Biol Med (Maywood). 2011 May 1;236(5):567-79. doi: 10.1258/ebm.2011.011007. Epub 2011 Apr 12.
Numerous studies have now documented a link between the immune infiltrate in several human carcinoma types and prognosis and response to therapy. The most comprehensive of these studies were in colorectal cancer with similar conclusions by numerous groups. Analyses of immune infiltrate of several other carcinoma types also showed general correlations between immune infiltrate and prognosis, but with some conflicting results. This review will attempt to summarize the current state of this field and point out what factors may be responsible for some of the conflicting findings. Nonetheless, the breadth of reports drawing similar conclusions for some cancer cell types leads one to more seriously consider the link between immune cell infiltrate and tumor prognosis and/or response to therapy, and the potential for combining conventional cancer therapy with active immunotherapy employing therapeutic cancer vaccines.
目前已有大量研究证实，几种人类癌症类型中的免疫浸润与预后和对治疗的反应之间存在关联。其中最全面的研究是在结直肠癌中进行的，许多研究小组得出了类似的结论。对其他几种癌症类型的免疫浸润分析也表明，免疫浸润与预后之间存在普遍相关性，但也存在一些相互矛盾的结果。本综述将尝试总结该领域的现状，并指出哪些因素可能导致部分研究结果存在冲突。尽管如此，对于一些癌症细胞类型，大量报告得出相似结论，这使得人们更加认真地考虑免疫细胞浸润与肿瘤预后和/或对治疗的反应之间的联系，以及将传统癌症治疗与使用治疗性癌症疫苗的主动免疫疗法相结合的可能性。
